STEL Technologies, LLC

Biotech · Private

CGEM graft, a tissue-engineered biological replacement for anterior cruciate ligament reconstruction using cell-generated matrix from mesenchymal stem cells

steltechnologies.com →
Grants
$1.7M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
1 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Validation and Cryopreservation of Ligament Engineered from Human Bone Marrow$222,922
Federal grantDepartment of Health and Human Services · Phase II · Cell-Generated Matrix (CGEM) Graft for Anterior Cruciate Ligament Repair.$999,993
Federal grantDepartment of Health and Human Services · Phase II · Cell-Generated Matrix (CGEM™) Graft for Anterior Cruciate Ligament Repair.$484,195
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2816Mineralys Therapeutics, Inc.—$118M
2817LYST THERAPEUTICS LLC——
2818Relation Therapeutics—$116M
2819STEL Technologies, LLC——
2820Passage Bio—$110M
2821Acadia Pharmaceuticals—$107M
2822Neurogene Inc.—$106M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.